Zosano Pharma Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, develops and seeks to commercialize therapeutics delivered via its proprietary intracutaneous microneedle patch system for rapid systemic administration of bioactive molecules, primarily targeting central nervous system disorders such as migraine; the lead product candidate is Qtrypta (M207), a zolmitriptan formulation for acute migraine treatment that bypasses gastrointestinal absorption for faster onset; the platform also supports peptides, small molecules, monoclonal antibodies, and vaccines, with historical focus on osteoporosis treatments like PTH patches. Founded in 2006 and headquartered in Fremont, California, the company operated principally in the United States, conducting research, development, and clinical trials from its Ardentech Court facility, which housed microneedle development labs, GMP manufacturing, and quality control. Zosano Pharma filed for voluntary Chapter 11 bankruptcy protection on June 1, 2022, in the U.S. Bankruptcy Court for the District of Delaware following FDA rejection of its Qtrypta new drug application resubmission and subsequent cash constraints; the court confirmed a liquidation plan on November 22, 2022, after which substantially all assets—including the microneedle array patch technology, intellectual property, license agreements, manufacturing equipment, and product packaging—sold for $1.25 million to Emergex Vaccines Holding Limited in August 2022, with ongoing post-confirmation administrative proceedings through 2025; the company ceased operations and went out of business as of December 7, 2022.
Microneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass Technologies
Why Zosano Pharma Shares Are Getting Hammered Today
Zosano Pharma Reports First Quarter 2022 Financial Results
Zosano Pharma Announces Additional Workforce Layoff
Zosano Pharma Provides Corporate Update
Is Zosano Pharma (ZSAN) Stock Really Up 3,000% Today?
Zosano Pharma (ZSAN) Stock: 1-For-35 Reverse Split Goes Into Effect
Zosano Pharma Announces Reverse Stock Split Effective Today
Best Stocks to Buy Under $5? Check These 3 Out
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Zosano Pharma (ZSAN) Stock: Why The Price Substantially Fell Today
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
Zosano Pharma Announces Publication Of Early Data On Influenza Vaccine
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
Zosano Pharma Corporation (ZSAN) Reports Q3 Loss, Misses Revenue Estimates
Zosano Pharma Reports Third Quarter 2021 Financial Results